17 – #MajorPROsASH – 2117 Schwaner
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
New publication 📝 Phase III results, published in Blood, show acalabrutinib + obinutuzumab significantly improved PFS and OS vs chlorambucil + obinutuzumab in treatment-naïve CLL (72-month PFS, 78.0% vs 17.2%; p < 0.0001).
Learn more: LymphomaHub.com
#CLLsm #leusm #MedNews #MedEd
🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
Missed out on #iwCLL2025?🩸
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
We had a fantastic time at #iwCLL2025 last week!🇵🇱
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
It's our first day onsite at #iwCLL2025 and we can't wait for two jam-packed days of expert interviews about all things CLL!🩸
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
Today is #WorldLeukemiaDay.🩸
Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ
Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧
#AMLsm #CLLsm #ALLsm #Leusm
The Phase Ib Safe Accelerated Venetoclax Escalation (SAVE) study explored an accelerated dose ramp-up of venetoclax in patients with CLL.
Learn more in our interview with the lovely Jennifer Crombie of @danafarber.bsky.social:
🎥 buff.ly/GzIwSol
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
It's always fantastic to catch up with @drmdavids.bsky.social of @danafarber.bsky.social!😄
At #18ICML, Dr Davids shared insights into the ReVenG trial, evaluating the safety & efficacy of venetoclax plus obinutuzumab retreatment in R/R CLL.
Watch now:
👉 buff.ly/5rzmgND 👈
#CLLsm #Leusm #Leukemia
We caught up with Adam Kittai at #EHA2025 to hear about the importance of the recently published consensus guidelines for Richter’s transformation, which aim to improve patient outcomes by unifying management practices & research:
🎥 👉 buff.ly/L4eLhvD
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky
In an insightful recent interview, Jacqueline Barrientos delves into fixed-duration versus continuous treatment with venetoclax-based regimens for CLL.
🎥 Watch here:
👉 buff.ly/1hgTKwR 👈
#CLLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
At #ICML18, Alexey Danilov of @cityofhope.bsky.social shared the promising results of a Phase I study evaluating bexobrutideg, a BTK degrader, in R/R CLL resistant to BTK inhibitors.
Watch the interview here:
🎥 buff.ly/cHVydMw
#CLLsm #Leusm #CTSM #TrialUpdate #HemOnc #BloodSky #HemeSky #MedSky
Want to hear insights into the real-world effectiveness of covalent BTK inhibitors in the first-line treatment of patients with symptomatic CLL?🩸
Check out our fantastic recent interview from #18ICML with Ryan Jacobs:
👉 buff.ly/7eXwIqV 👈
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky
